The immune privileged retina mediates an alternative activation of J774A.1 cells

Ocular Immunology and Inflammation

Volumn 17, Issue 6, 2009, Pages 380-389

  Lau, Chun H ^a   Taylor, Andrew W ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Immune privilege; Immunosuppression; Neuropeptides; Posterior eyecups

Indexed keywords

ALPHA INTERMEDIN; ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; MACROPHAGE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM;

ALPHA-MSH; ANIMALS; CELL LINE; CULTURE MEDIA; CYTOKINES; ENDOTOXINS; FEMALE; IMMUNE TOLERANCE; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; NITRIC OXIDE; RETINA; RETINAL PIGMENT EPITHELIUM; TISSUE CULTURE TECHNIQUES;

EID: 72449147220     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903118642     Document Type: Article

References (41)

1. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol. 2003;74(2):179-185.
2. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy. 2007;92:71-85.
3. Bok, D. Evidence for an inflammatory process in agerelated macular degeneration gains new support. Proc Natl Acad Sci USA. 2005;102(20):7053-7054.
4. Boulton M, Dayhaw-Barker P. The role of the retinal pigment epithelium: topographical variation and ageing changes. Eye. 2001;15(Pt 3):384-389.
5. Steinberg RH. Interactions between the retinal pigment epithelium and the neural retina. Doc Ophthalmol. 1985;60(4):327-346.
6. Finnemann SC. Focal adhesion kinase signaling promotes phagocytosis of integrin-bound photoreceptors. Embo J. 2003;22(16):4143-4154.
7. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause etinitis pigmentosa. Nat Genet. 2000;26(3):270-271.
8. Strauss O, Stumpff F, Mergler S, et al. The Royal College of Surgeons rat: an animal model for inherited retinal degeneration with still unknown genetic defect. Acta Anat (Basel). 1998;162(2-3):101-111.
9. Jiang LQ, Jorquera M, Streilein, JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal llografts. Invest Ophthalmol Vis Sci. 1993;34(12):3347-3354.
10. Wenkel H, Streilein JW. Evidence that retinal pigment epithelium functions as an immune-privileged tissue. Invest Ophthalmol Vis Sci. 2000;41(11):3467-3473.
11. Ng TF, Osawa H, Hori J, et al. Allogeneic neonatal neuronal retina grafts display partial immune privilege in the subcapsular space of the kidney. J Immunol. 2002;169(10):5601-5606.
12. Streilein JW, Ma N, Wenkel H, et al. Immunobiology and privilege of neuronal retina and pigment epithelium transplants. Vision Res. 2002;42(4):487-495.
13. Griffith TS, Ferguson, TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18(5):240-244.
14. Jorgensen A, Wiencke AK, la Cour M, et al. Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci. 1998;39(9):1590-1599.
15. Zamiri P, Masli S, Streilein JW, et al. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci. 2006;47(9):3912-3918.
16. Zamiri P, Masli S, Kitaichi N, et al. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci. 2005;46(3):908-919.
17. Tanihara H, Yoshida M, Matsumoto M, et al. Identification of transforming growth factor-beta expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1993;34(2):413-419.
18. Ishida K, Panjwani N, Cao Z, et al. Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms. Ocul Immunol Inflamm. 2003;11(2):91-105.
19. Gregerson DS, Heuss ND, Lew KL, et al. Interaction of retinal pigmented epithelial cells and CD4 T cells leads to T-cell anergy. Invest Ophthalmol Vis Sci. 2007;48(10):4654-4663.
20. Sugita S, Keino H, Futagami Y, et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci. 2006;47(12):5376-5384.
21. Sugita S, Ng TF, Lucas PJ, et al. B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells. J Immunol. 2006;176(1):118-127.
22. Wenkel H, Streilein JW. Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci. 1998;39(10):1823-1834.
23. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879-889.
24. Kezic J, McMenamin PG. Differential turnover rates of monocyte-derived cells in varied ocular tissue microenvironments. J Leukoc Biol. 2008;84(3):721-729.
25. Kezic J, Xu H, Chinnery HR, et al. Retinal microglia and uveal tract dendritic cells and macrophages are not CX3CR1 dependent in their recruitment and distribution in the young mouse eye. Invest Ophthalmol Vis Sci. 2008;49(4):1599-1608.
26. Xu H, Chen M, Mayer EJ, et al. Turnover of resident retinal microglia in the normal adult mouse. Glia. 2007;55(11):1189-1198.
27. Broderick C, Duncan L, Taylor N, et al. IFN-gamma and LPS-mediated IL-10-dependent suppression of retinal microglial activation. Invest Ophthalmol Vis Sci. 2000;41(9):2613-2622.
28. Zamiri P, Zhang Q, Streilein JW. Vulnerability of allogeneic retinal pigment epithelium to immune T-cell-mediated damage in vivo and in vitro. Invest Ophthalmol Vis Sci. 2004;45(1):177-184.
29. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol. 1994;153(3):1080-1086.
30. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 1992;11(12):1199-1206.
31. Sonoda KH, Sakamoto T, Qiao H, et al. The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology. 2005;116(3):390-399.
32. Luger TA, Scholzen TE, Brzoska T, et al. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.
33. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunology Today. 1997;18(3):140-145.
34. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35.
35. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677-686.
36. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
37. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv Exp Med Biol. 2007;601:213-223.
38. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791-5802.
39. Bronte V, Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641-654.
40. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88- dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007;204(6):1463-1474.
41. Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67(20):10019-10026.